Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Urinary Bladder Neoplasms × Meropenem × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Febrile Neutropenia 3 Neoplasms 2 Urinary Bladder Neoplasms 1 Sepsis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Other Infectious Diseases 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Emergencies 1

Interventions

Gemcitabine 73 Cisplatin 56 Cystectomy 35 pembrolizumab 30 Docetaxel 21 Nivolumab 20 durvalumab 19 Paclitaxel 16 Radiotherapy 15 Magnetic Resonance Spectroscopy 15 Mitomycin 13 Carboplatin 13 Doxorubicin 12 Cystoscopy 12 atezolizumab 11 Standard of Care 11 avelumab 10 BCG Vaccine 10 Surveys and Questionnaires 9 Sunitinib 9 tremelimumab 8 Specimen Handling 8 Ipilimumab 8 Filgrastim 8 Blood Specimen Collection 8 Transurethral Resection of Bladder 7 Neoadjuvant Therapy 7 Methotrexate 7 Methods 7 Early Intervention, Educational 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05392634 2022-05-31

MACS

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡